| 1. Fridman JS, Scherle PA, Collins R, Burn TC, Li Y, Li J, Covington MB, Thomas B, Collier P, Favata MF et al.. (2010) Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050.. J Immunol, 184 (9): (5298-307). [PMID:20363976] |
| 2. Genovese MC, Kremer J, Zamani O, Ludivico C, Krogulec M, Xie L, Beattie SD, Koch AE, Cardillo TE, Rooney TP et al.. (2016) Baricitinib in Patients with Refractory Rheumatoid Arthritis.. N Engl J Med, 374 (13): (1243-52). [PMID:27028914] |
| 3. Kennedy Crispin M, Ko JM, Craiglow BG, Li S, Shankar G, Urban JR, Chen JC, Cerise JE, Jabbari A, Winge MC et al.. (2016) Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata.. JCI Insight, 1 (15): (e89776). [PMID:27699252] |
| 4. Mackay-Wiggan J, Jabbari A, Nguyen N, Cerise JE, Clark C, Ulerio G, Furniss M, Vaughan R, Christiano AM, Clynes R. (2016) Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata.. JCI Insight, 1 (15): (e89790). [PMID:27699253] |
| 5. Xing L, Dai Z, Jabbari A, Cerise JE, Higgins CA, Gong W, de Jong A, Harel S, DeStefano GM, Rothman L et al.. (2014) Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition.. Nat Med, 20 (9): (1043-9). [PMID:25129481] |
| 6. Jabbari A, Dai Z, Xing L, Cerise JE, Ramot Y, Berkun Y, Sanchez GA, Goldbach-Mansky R, Christiano AM, Clynes R et al.. (2015) Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib.. EBioMedicine, 2 (4): (351-5). [PMID:26137574] |
| 7. Richardson P, Griffin I, Tucker C, Smith D, Oechsle O, Phelan A, Stebbing J. (2020) Baricitinib as potential treatment for 2019-nCoV acute respiratory disease.. Lancet, 395 (10223): (e30-e31). [PMID:32032529] |
| 8. Stebbing J, Phelan A, Griffin I, Tucker C, Oechsle O, Smith D, Richardson P. (2020) COVID-19: combining antiviral and anti-inflammatory treatments.. Lancet Infect Dis, 20 (4): (400-402). [PMID:32113509] |
B1512012